Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
CONTEXT: Levothyroxine monotherapy is the treatment of choice for hypothyroid patients because peripheral T4 to T3 conversion is believed to account for the overall tissue requirement for thyroid hormones. However, there are indirect evidences that this may not be the case in all patients. OBJECTIVE: To evaluate in a large series of athyreotic patients whether levothyroxine monotherapy can normalize serum thyroid hormones and thyroid-pituitary feedback. DESIGN: Retrospective study. SETTING: Academic hospital. PATIENTS: 1,811 athyreotic patients with normal TSH levels under levothyroxine monotherapy and 3,875 euthyroid controls. MEASUREMENTS: TSH, FT4 and FT3 concentrations by immunoassays. RESULTS: FT4 levels were significantly higher and FT3 levels were significantly lower (p<0.001 in both cases) in levothyroxine-treated athyreotic patients than in matched euthyroid controls. Among the levothyroxine-treated patients 15.2% had lower serum FT3 and 7.2% had higher serum FT4 compared to euthyroid controls. A wide range of FT3/FT4 ratios indicated a major heterogeneity in the peripheral T3 production capacity in different individuals. The correlation between thyroid hormones and serum TSH levels indicated an abnormal feedback mechanism in levothyroxine-treated patients. CONCLUSIONS: Athyreotic patients have a highly heterogeneous T3 production capacity from orally administered levothyroxine. More than 20% of these patients, despite normal TSH levels, do not maintain FT3 or FT4 values in the reference range, reflecting the inadequacy of peripheral deiodination to compensate for the absent T3 secretion. The long-term effects of chronic tissue exposure to abnormal T3/T4 ratio are unknown but a sensitive marker of target organ response to thyroid hormones (serum TSH) suggests that this condition causes an abnormal pituitary response. A more physiological treatment than levothyroxine monotherapy may be required in some hypothyroid patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These changes are an increase in T4 or free T4 (fT4) levels, an increase in fT4/T3 ratios, associated with a decline in T3 or free T3 (fT3) levels.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, in children and adults with an intact HPT axis, fT3 levels do not correlate with TSH levels (and in children they show a positive rather than the negative correlation seen with fT4) (11,87).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, low FT3 and an increased FT4/FT3 ratio after thyroidectomy has been reported in about 15% of a large unselected population (102).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lean body mass is not the only variable to estimate the therapeutic post-thyroidectomy LT4 dose, owing to the disappearance of thyroidal contribution to circulating T3 (102).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, Levothyroxine affects the T3:T4 ratio and individuals on levothyroxine have relatively low FT3: FT4 ratios [110].”
From Age-related variation in thyroid function – a narrative review highlighting important implications for research and clinical practice (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853 · cited 1×
“he insufficient T3 peripheral production cannot be appropriately corrected by increasing levothyroxine dose because the inhibitory effect of elevated T4 on type II deiodinase [27,28] will end up increasing the imbalance of the circulating FT3/FT4 ratio (Figure 3).”
Deiodinases: implications of the local control of thyroid hormone action
Bianco, A. C., & Kim, B. W. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29812 · Cited by 845
Selenium, the Thyroid, and the Endocrine System
Köhrle, J., Jakob, F., Contempré, B., & Dumont, J. E. (2005) · Endocrine Reviews · doi:10.1210/er.2001-0034 · Cited by 529 · cited 1×
“function [23,24,25] and also abnormal thyroid hormone metabolism independent from deiodination [26].”
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 2×
“Their condition may ameliorate under a combined T4-T3 treatment [1,18,19,20].”
Zulewski, H., Müller, B., Exer, P., Miserez, A. R., & Staub, J.-J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3810 · Cited by 338 · cited 1×
“secreted TSH may not reflect what happens in other target tissues and, therefore, in some instances serum TSH may not be an appropriate indicator of peripheral tissue euthyroidism [7,8,9].”
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327 · cited 1×
“Their condition may ameliorate under a combined T4-T3 treatment [1,18,19,20].”
Wekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299 · cited 1×
“It should be underlined, however, that no long-term study is available to assess that the abnormal circulating thyroid hormone ratio has no adverse effect and that even short-term studies indicate that some hypothyroid patients do not reach a condition of well-being and emotional satisfaction under levothyroxine monot…”
Grozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296 · cited 2×
“general well-being under levothyroxine monotherapy and (iii) that in many studies a short period of T4-T3 combination therapy has not caused a significant improvement in a variety of symptoms, the conclusion has been drown that levothyroxine monotherapy must be the standard treatment for all hypothyroid patients [16].”
Escobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287 · cited 3×
“The major source of T3 within peripheral tissues comes from the circulating T3 pool and the variable portion coming from locally deiodinated T4 within each tissue might be not adequate according to animal experiments [5].”
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“However, three cross-sectional studies comparing LT4-treated patients with control subjects showed that despite similar TSH values the patients had significantly lower T3 concentrations (40,41,43).”
InfluentialChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Deiodinases and their intricate role in thyroid hormone homeostasis
Luongo, C., Dentice, M., & Salvatore, D. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0218-2 · Cited by 332
Paradigms of dynamic control of thyroid hormone signaling
Bianco, A. C., Dumitrescu, A., Gereben, B., Ribeiro, M. O., Fonseca, T. L., Fernandes, G. W., & Bocco, B. M. L. C. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00275 · Cited by 293
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
“In a recent large cross-sectional study of 1880 athyreotic patients on L-T4 treatment, serum T3 levels were significantly lower, although still within the normal reference range, compared with the levels observed in 3875 matched euthyroid controls (29).”
BackgroundResultAn Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231
“Among National Health and Nutrition Examination Survey (NHANES) participants, LT4-treated patients with a normal serum TSH exhibit a 15–20% decrease in the ratio of circulating T3/T4 (18), and about 15% of these patients may not maintain normal serum T3 levels (19).”
Treatment for primary hypothyroidism: current approaches and future possibilities
Vaidya, B., Chakera, & Pearce (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s12894 · Cited by 199
“…many patients on levothyroxine do not achieve a physiological Free T3/Free T4 (FT3/FT4) ratio despite serum TSH being within the reference range, 47,48 suggesting that hepatic and renal conversion of thyroxine to triiodothyronine may be impaired in these patients and this may account for the…”
Werneck de Castro, J. P., Fonseca, T. L., Ueta, C. B., McAninch, E. A., Abdalla, S., Wittmann, G., Lechan, R. M., Gereben, B., & Bianco, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77588 · Cited by 184
“This scenario is partially supported by 2 factors: First, serum T3 is below the lower limit of the reference range in approximately 15% of the hypothyroid patients treated with L-T4 monotherapy, despite normal serum levels of TSH and a relatively higher serum free T4 (6, 7).”
Is a Normal TSH Synonymous With “Euthyroidism” in Levothyroxine Monotherapy?
Peterson, S. J., McAninch, E. A., & Bianco, A. C. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2660 · Cited by 182
“One hypothesis to explain this phenomenon is that serum levels of T3 might not be fully normalized, (8) ie, T4-to-T3 conversion in these patients may be insufficient to restore levels to those achieved when thyroidal secretion of T3 is intact.”
BackgroundJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
“Gullo et al. (11) showed that in 1811 athyreotic individuals on LT4 replacement that the fT3:fT4 ratio (0.24, interquartile range 0.20–0.28) was significantly lower than in 3875 normal individuals with an intact HPT axis (0.32, interquartile range 0.27–0.37), p < 0.001, despite similar TSH levels…”
InfluentialDietrich, J. W., Landgrafe-Mende, G., Wiora, E., Chatzitomaris, A., Klein, H. H., Midgley, J. E. M., & Hoermann, R. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00057 · Cited by 164
“It is increased in Graves’ disease compared to multinodular toxic goiter and toxic adenoma (51) and decreased in athyreotic patients receiving substitution therapy with -T4 (54).”
BackgroundDIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients
Castagna, M. G., Dentice, M., Cantara, S., Ambrosio, R., Maino, F., Porcelli, T., Marzocchi, C., Garbi, C., Pacini, F., & Salvatore, D. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2587 · Cited by 151
“1624 Castagna et al DIO2 Thr92Ala and Reduced FT4-FT3Conversion on LT4 Therapy J Clin EndocrinolMetab,May 2017, 102(5):1623–1630”
BackgroundInfluentialDefending plasma T3 is a biological priority
Abdalla, S. M., & Bianco, A. C. (2014) · Clinical Endocrinology · doi:10.1111/cen.12538 · Cited by 147
TSH and thyrotropic agonists: key actors in thyroid homeostasis
Dietrich, J. W., Landgrafe, G., & Fotiadou, E. H. (2012) · Journal of Thyroid Research · doi:10.1155/2012/351864 · Cited by 146
“Persons with abnormal sum activity of deiodinases, however, might benefit from additional treatment with liothyronine [414, 423], although this does not hold true for all polymorphisms of deiodinases [424].”
BackgroundScope and limitations of iodothyronine deiodinases in hypothyroidism
Gereben, B., McAninch, E. A., Ribeiro, M. O., & Bianco, A. C. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.155 · Cited by 146
“Given that the rat model reproduces the findings observed among patients treated with levothyroxine, it is expected that similar pathways in humans provide the mechanistic basis for the observation of increased serum T4:T3 ratio in the setting of normalized serum TSH levels that are frequently observed among levothyro…”
BackgroundResultHomeostatic control of the thyroid-pituitary axis: perspectives for diagnosis and treatment
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00177 · Cited by 143
“This may explain why athyreotic patients are particularly vulnerable, with approximately 15% living in a chronically low-T3 state below reference, even if they are able to normalize TSH (122, 198).”
BackgroundIto, M., Miyauchi, A., Morita, S., Kudo, T., Nishihara, E., Kihara, M., Takamura, Y., Ito, Y., Kobayashi, K., Miya, A., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1029 · Cited by 133
Taylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128
Cappola, A. R., Desai, A. S., Medici, M., Cooper, L. S., Egan, D., Sopko, G. S., Fishman, G. I., Goldman, S., Cooper, D. S., Mora, S., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036859 · Cited by 169
Combination Treatment with T4 and T3: Toward Personalized Replacement Therapy in Hypothyroidism?
Biondi, B., & Wartofsky, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3399 · Cited by 124
The history and future of treatment of hypothyroidism
McAninch, E. A., & Bianco, A. C. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1799 · Cited by 118
“In a large study of approximately 3800 healthy individuals (4), the serum free T4:free T3 ratio was around 3, as opposed to a ratio of 4 in more than 1800 patients who had undergone thyroidectomy and were receiving L-thyroxine monotherapy.”
Hypothyroidism and Thyroiditis
Brent, G. A., & Davies, T. F. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00013-4 · Cited by 126
Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism
Wiersinga, W. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.258 · Cited by 114
Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
Centanni, M., Benvenga, S., & Sachmechi, I. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0706-y · Cited by 113
“Thus, some patients may require a more “physiological” treatment than levothyroxine monotherapy [75].”
BackgroundType 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain
Jo, S., Fonseca, T. L., Bocco, B. M. L. C., Fernandes, G. W., McAninch, E. A., Bolin, A. P., Da Conceição, R. R., Werneck-de-Castro, J. P., Ignacio, D. L., Egri, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123176 · Cited by 107
Wouters, H. J. C. M., van Loon, H. C. M., van der Klauw, M. M., Elderson, M. F., Slagter, S. N., Kobold, A. M., Kema, I. P., Links, T. P., van Vliet-Ostaptchouk, J. V., & Wolffenbuttel, B. H. R. (2017) · Thyroid® · doi:10.1089/thy.2016.0199 · Cited by 97
“(6) showed that free T4 (fT4) levels were significantly higher and that free triiodothyronine (fT3) levels and the fT3/fT4 ratio were significantly lower during”
Genetic determination of the hypothalamic–pituitary–thyroid axis: where do we stand?
Medici, M., Visser, W. E., Visser, T. J., & Peeters, R. P. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1081 · Cited by 92
“tomized patients on LT4 replacement have low serum T3 despite normal TSH and high-normal FT4 levels (134).”
BackgroundMcAninch, E. A., Rajan, K. B., Miller, C. H., & Bianco, A. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01361 · Cited by 94
Cappola, A. R., Desai, A. S., Medici, M., Cooper, L. S., Egan, D., Sopko, G., Fishman, G. I., Goldman, S., Cooper, D. S., Mora, S., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0416 · Cited by 94
“Individuals with normal TSH levels who are taking levothyroxine therapy have higher serum free T4 concentrations while taking levothyroxine than when they were in the euthyroid state before a thyroidectomy (57) or compared with individuals in the euthyroid state not taking levothyroxine (58).”
BackgroundMcAninch, E. A., Jo, S., Preite, N. Z., Farkas, E., Mohácsik, P., Fekete, C., Egri, P., Gereben, B., Li, Y., Deng, Y., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4092 · Cited by 93
“While much additional investigation is still needed, it is conceivable that compensatory mechanisms developed in carriers of the Ala92-D2 polymorphism lose effectiveness in the setting of treatment with L-T4, when patients exhibit an elevation in serum T4/T3 ratio (45, 46).”
BackgroundBiochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy
Ito, M., Miyauchi, A., Hisakado, M., Yoshioka, W., Ide, A., Kudo, T., Nishihara, E., Kihara, M., Ito, Y., Kobayashi, K., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0426 · Cited by 91
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Hoermann, R., Midgley, J. E. M., Giacobino, A., Eckl, W. A., Wahl, H. G., Dietrich, J. W., & Larisch, R. (2014) · Clinical Endocrinology · doi:10.1111/cen.12527 · Cited by 82
Thyroid Hormone Suppression Therapy
Biondi, B., & Cooper, D. S. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.10.008 · Cited by 81
Mitchell, A. L., Hegedüs, L., Žarković, M., Hickey, J. L., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14340 · Cited by 81
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
When thyroid hormone replacement is ineffective?
Benvenga, S. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000003 · Cited by 74
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
Taylor, P. N., Lansdown, A., Witczak, J., Khan, R., Rees, A., Dayan, C. M., & Okosieme, O. (2023) · Thyroid Research · doi:10.1186/s13044-023-00149-5 · Cited by 72
“Also, Levothyroxine affects the T3:T4 ratio and individuals on levothyroxine have relatively low FT3: FT4 ratios [110].”
BackgroundNakamura, T., Miyauchi, A., Ito, Y., Ito, M., Kudo, T., Tanaka, M., Kohsaka, K., Kasahara, T., Nishihara, E., Fukata, S., et al. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0201 · Cited by 81
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00364 · Cited by 69
“FT3 is displaced from TSH in these patients, being relatively lower at the same TSH level (33, 85).”
BackgroundTo Treat or Not to Treat Subclinical Hypothyroidism, What Is the Evidence?
Calissendorff, J., & Falhammar, H. (2020) · Medicina · doi:10.3390/medicina56010040 · Cited by 90
“In a study of thyroidectomized patients (n = 1811), all on levothyroxine substitution, fT4 was slightly higher, and fT3 lower (within the normal range), compared to the levels of euthyroid patients (n = 3875) without thyroid medication [59].”
Predicting outcomes and complications following radioiodine therapy in Graves’ thyrotoxicosis
Aung, E. T., Zammitt, N. N., Dover, A. R., Strachan, M. W. J., Seckl, J. R., & Gibb, F. W. (2018) · Clinical Endocrinology · doi:10.1111/cen.13873 · Cited by 74
T3 levels and thyroid hormone signaling
Salas-Lucia, F., & Bianco, A. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1044691 · Cited by 66
Hypothyroidism: The difficulty in attributing symptoms to their underlying cause
Jansen, H. I., Boelen, A., Heijboer, A. C., Bruinstroop, E., & Fliers, E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130661 · Cited by 63
“The assumption is that L-T4 substitution alone does not suffice, as it leads to low/lownormal (F)T3 and high FT4 concentrations in the presence of TSH concentrations within the reference interval (32).”
BackgroundResultDayan, C., & Panicker, V. (2018) · Thyroid Research · doi:10.1186/s13044-018-0045-x · Cited by 62
Levothyroxine: conventional and novel drug delivery formulations.
Liu, H., Li, W., Zhang, W., Sun, S., & Chen, C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac030 · Cited by 63
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0819 · Cited by 59
Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism
Idrees, T., Palmer, S., Maciel, R. M. B., & Bianco, A. C. (2020) · Thyroid® · doi:10.1089/thy.2020.0153 · Cited by 58
Ku, E. J., Yoo, W. S., Lee, E. K., Ahn, H. Y., Woo, S. H., Hong, J. H., Chung, H. K., & Park, J.-W. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab539 · Cited by 57
THERAPY OF ENDOCRINE DISEASE: T4 + T3 combination therapy: is there a true effect?
Wiersinga, W. M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0645 · Cited by 52
Ito, M., Miyauchi, A., Kang, S., Hisakado, M., Yoshioka, W., Ide, A., Kudo, T., Nishihara, E., Kihara, M., Ito, Y., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0138 · Cited by 51
Leow, M. K.-S., & Goede, S. L. (2014) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-11-35 · Cited by 51
“Another equally important contributory factor to these distressing incongruent clinical outcomes is the differential recovery rates in the spatiotemporal attainment of equilibrium between molecular, cellular, tissue, organ, systemic and biochemical euthyroidism, currently a subject of intense research [7,39].”
BackgroundSleep deprivation alters thyroid hormone economy in rats
Rodrigues, N. C., da Cruz, N. S., Nascimento, C. D. P., da Conceição, R. R., da Silva, A. C. M., Olivares, E. L., & Marassi, M. P. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2014.083303 · Cited by 66
“Curiously, it has already been demonstrated that athyreotic patients often have a normal TSH and T4 and a highly heterogeneous capacity for T3 production after receiving oral levothyroxine (Gullo et al. 2011).”
BackgroundHypothyroidism and Its Rapid Correction Alter Cardiac Remodeling
Hajje, G., Saliba, Y., Itani, T. M., Moubarak, M., Aftimos, G., & Farès, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109753 · Cited by 54
“However, the beneficial therapeutic effects obtained in the short term might be followed by pathological manifestations of the systemic effects of thyroid hormones during longer treatments [81,82, 83,84].”
BackgroundHennessey, J. V., & Espaillat, R. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13062 · Cited by 49
Massolt, E. T., van der Windt, M., Korevaar, T. I. M., Kam, B. L. R., Burger, J. W., Franssen, G. J. H., Lehmphul, I., Köhrle, J., Visser, W. E., & Peeters, R. P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13101 · Cited by 47
Biondi, B., Bartalena, L., Chiovato, L., Lenzi, A., Mariotti, S., Pacini, F., Pontecorvi, A., Vitti, P., & Trimarchi, F. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0511-z · Cited by 44
Combination L-T3 and L-T4 therapy for hypothyroidism
Wartofsky, L. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/01.med.0000432611.03732.49 · Cited by 42
“One such polymorphism in the D2 gene, Thr92Ala [43], has been shown to be associated with reduced T4 to T3 activation in skeletal muscle and thyroid [44].”
BackgroundInfluentialThe relevance of T3 in the management of hypothyroidism
Salvatore, D., Porcelli, T., Ettleson, M. D., & Bianco, A. C. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00004-3 · Cited by 41
Kaminski, J., Miasaki, F. Y., Paz-Filho, G., Graf, H., & Carvalho, G. A. D. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000192 · Cited by 42
“Evidence from thyroidectomized animal and human studies suggests that thyroid hormone replacement therapy in the form of LT4 is not sufficient to lead to euthyroidism or to replenish 100% of the circulating and tissular T3, even assuming that peripheral conversion from T4 to T3 is normal (18,19).”
BackgroundRoss, D. S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13410 · Cited by 42
Roef, G. L., Taes, Y., Kaufman, J., daele, C. M. V., Buyzere, M. D., Gillebert, T. C., & Rietzschel, E. R. (2013) · Thyroid · doi:10.1089/thy.2012.0471 · Cited by 45
“General characteristics Age (years) 45 [40–50] 46 [41–51] Height (cm) 163– 6 176 – 7 Weight (kg) 65.”
Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019) · Drugs in Context · doi:10.7573/dic.212597 · Cited by 41
Epidemiology of thyroid disorders in the Lifelines Cohort Study (the Netherlands)
Wouters, H. J. C. M., Slagter, S. N., Kobold, A. C. M., van der Klauw, M. M., & Wolffenbuttel, B. H. R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242795 · Cited by 48
“001 in both cases) in levothyroxine-treated athyreotic patients than in matched euthyroid control subjects [40].”
ResultKorevaar, T. I. M., Leung, A. M., Alexander, E. K., Bliddal, S., Boelaert, K., Brenta, G., Chou, R., Dhillon‐Smith, R. K., Dosiou, C., Eaton, J. L., et al. (2026) · Thyroid · doi:10.1177/10507256261445624 · Cited by 66
Guglielmi, R., Frasoldati, A., Zini, M., Grimaldi, F., Gharib, H., Garber, J. R., & Papini, E. (2016) · Endocrine Practice · doi:10.4158/ep161308.or · Cited by 39
Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level
Jonklaas, J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000355 · Cited by 38
Das, D., Banerjee, A., Jena, A. B., Duttaroy, A. K., & Pathak, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112613 · Cited by 50
Yi, W., Kim, B. H., Kim, M., Kim, J., Im, M., Ryang, S., Kim, E. H., Jeon, Y. K., Kim, S. S., & Kim, I. J. (2022) · Thyroid · doi:10.1089/thy.2021.0634 · Cited by 36
Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism
Russo, M., Scollo, C., Pellegriti, G., Cotta, O. R., Squatrito, S., Frasca, F., Cannavò, S., & Gullo, D. (2016) · Clinical Endocrinology · doi:10.1111/cen.12868 · Cited by 36
Self-citationEmerging Therapies in Hypothyroidism
Bianco, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-060622-101007 · Cited by 44
Liothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality
Planck, T., Hedberg, F., Calissendorff, J., & Nilsson, A. (2021) · Thyroid® · doi:10.1089/thy.2020.0388 · Cited by 35
“LT4 treatment results in relatively higher normal levels of free thyroxine (T4) and relatively lower levels of free triiodothyronine (T3) than in euthyroid subjects without treatment (7,8), but the clinical relevance of this finding is unclear.”
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2016) · European Thyroid Journal · doi:10.1159/000447967 · Cited by 35
T4 + T3 combination therapy: any progress?
Wiersinga, W. M. (2019) · Endocrine · doi:10.1007/s12020-019-02052-2 · Cited by 35
Piticchio, T., Frasca, F., Malandrino, P., Trimboli, P., Carrubba, N., Tumminia, A., Vinciguerra, F., & Frittitta, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1200372 · Cited by 47
“When heterogeneity was found, subgroup and metaregression analyses were performed to explore the causes using several covariates (i.e., sample size, continent, duration of GFD, mean age, mean BMI, LT4 therapy, and GRC patients included).”
BackgroundInfluentialSelf-citationThe role of functional thyroid capacity in pituitary thyroid feedback regulation
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13003 · Cited by 35
“Nor does it raise FT3 to levels observed in the healthy population when TSH returns into the reference range.(33,34) The impaired equilibria have been well recognised, being also associated with patient complaints during follow‐up in LT4‐ treated patients with thyroid carcinoma.”
BackgroundCentanni, M., Duntas, L., Feldt-Rasmussen, U., Koehrle, J., Peeters, R. P., Razvi, S., Trimboli, P., & Virili, C. (2025) · European Thyroid Journal · doi:10.1530/etj-25-0123 · Cited by 38
“Lean body mass is not the only variable to estimate the therapeutic post-thyroidectomy LT4 dose, owing to the disappearance of thyroidal contribution to circulating T3 (102).”
Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal
Van Tassell, B., Wohlford, G. F., Linderman, J. D., Smith, S., Yavuz, S., Pucino, F., & Celi, F. S. (2019) · Thyroid® · doi:10.1089/thy.2019.0101 · Cited by 31
“This modality is associated with a shift in the T4:T3 ratio (27) that is commonly explained by the lack of endogenous production to T3, potentially causing residual hypothyroid symptoms in a significant minority of patients (6).”
BackgroundAzizi, F. (2020) · Thyroid · doi:10.1089/thy.2019.0814 · Cited by 35
“Patients on levothyroxine (LT4) replacement may exhibit significant impairment in psychological well-being (18) and lower resting energy expenditure, compared with normal controls (19,20).”
Chambers, T., Anney, R., Taylor, P. N., Teumer, A., Peeters, R. P., Medici, M., Caseras, X., & Rees, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa903 · Cited by 36
“Since direct effects on volume loss still remained when controlling for BMI, other mechanisms may also be in operation, including reduced T3 signaling, as patients established on levothyroxine replacement for hypothyroidism display reduced serum T3 levels despite normalization of TSH (34).”
BackgroundInfluentialThyroid Hormone Replacement Therapy: Three Simple Questions, Complex Answers
Bianco, A. C., & Casula, S. (2012) · European Thyroid Journal · doi:10.1159/000339447 · Cited by 32
Santini, F., Giannetti, M., Ricco, I., Querci, G., Saponati, G., Bokor, D., Rivolta, G., Bussi, S., Braverman, L. E., Vitti, P., et al. (2014) · Endocrine Practice · doi:10.4158/ep13331.or · Cited by 31
Del Duca, S. C., Santaguida, M. G., Brusca, N., Gatto, I., Cellini, M., Gargano, L., Verga Falzacappa, C., Frattaroli, F. M., Virili, C., & Centanni, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0314 · Cited by 31
Midgley, J. E. M., Larisch, R., Dietrich, J. W., & Hoermann, R. (2015) · Endocrine Connections · doi:10.1530/ec-150056 · Cited by 31
“In two studies, approximately 15% of athyreotic patients could not even raise 297 their FT3 above the lower reference limit on L-T4 (19,20).”
BackgroundSustained release T3 therapy: animal models and translational applications
Idrees, T., Price, J. D., Piccariello, T., & Bianco, A. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00544 · Cited by 30
“In a series of approximately 2,000 LT4-treated hypothyroid patients, serum T3 is relatively lower and serum T4 is relatively higher when compared to control individuals; in about 15% of the patients, serum T3 is below normal range (22).”
BackgroundDiStefano, J., & Jonklaas, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00746 · Cited by 28
“This interest has been spurred, in part, by the welldocumented finding that the ratio of total thyroxine (T4) to total triiodothyronine (T3) increases during LT4 therapy, compared with endogenous euthyroidism (5), and also that T3 levels may be lower than in the native state (6).”
BackgroundFatigue and quality of life among thyroid cancer survivors without persistent or recurrent disease
Maki, Y., Horiuchi, K., & Okamoto, T. (2022) · Endocrine Connections · doi:10.1530/ec-21-0506 · Cited by 34
“This is because there is no production of fT3 from the thyroid gland following total thyroidectomy (42-43).”
BackgroundSchlenker, E. H. (2012) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2012.02.007 · Cited by 30
Risks and safety of combination therapy for hypothyroidism
Jonklaas, J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1182019 · Cited by 27
Larisch, R., Midgley, J., Dietrich, J. W., & Hoermann, R. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-125064 · Cited by 30
Pang, X., Pu, T., Xu, L., & Sun, R. (2020) · Clinical Endocrinology · doi:10.1111/cen.14172 · Cited by 26
Critical Approach to Hypothyroid Patients With Persistent Symptoms
Biondi, B., Celi, F. S., & McAninch, E. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad224 · Cited by 34
Serum thyrotropin and triiodothyronine levels in levothyroxine-treated patients
Ettleson, M. D., Prieto, W. H., Russo, P. S. T., de Sa, J., Wan, W., Laiteerapong, N., Maciel, R. M. B., & Bianco, A. C. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac725 · Cited by 25
Treatment of congenital thyroid dysfunction: Achievements and challenges
Krude, H., Kühnen, P., & Biebermann, H. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.04.004 · Cited by 30
Borson‐Chazot, F., Terra, J., Goichot, B., & Caron, P. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071386 · Cited by 37
Long-term thionamide antithyroid treatment of Graves' disease
Azizi, F., Abdi, H., Amouzegar, A., & Moeini, A. S. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101631 · Cited by 31
The Swinging Pendulum in Treatment for Hypothyroidism: From (and Toward?) Combination Therapy
McAninch, E. A., & Bianco, A. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00446 · Cited by 24
Lee, Y. K., Lee, H., Han, S., Jung, H., Shin, D. Y., Nam, K.-H., Chung, W. Y., & Lee, E. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081106 · Cited by 24
“In the previous studies, thyroidectomized patients had lower TSH levels when their free T3 levels are similar to those at the preoperative stage or those of controls with normal thyroid function [7,8,14,15].”
Background
Metadata
- Authors
- Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R.
- Affiliations
- University of Catania (IT)
- Corresponding author
- Gullo, Damiano
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-08-01
- Volume
- 6
- Issue
- 8
- Pages
- e22552
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3148220
- OpenAlex
- W2163820892
- Cited by
- 307
- References
- 32
- Citations by year
- 2026: 14 · 2025: 25 · 2024: 20 · 2023: 26 · 2022: 27 · 2021: 25 · 2020: 31 · 2019: 30 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 18 · 2014: 12 · 2013: 9 · 2012: 10
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Università di Catania
- Associazione Italiana per la Ricerca sul Cancro
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- levothyroxine monotherapy, athyreosis, hypothyroidism, free triiodothyronine, free thyroxine, T3/T4 ratio, thyroid-stimulating hormone, euthyroidism
- MeSH terms
- Humans, Hypothyroidism, Immunoenzyme Techniques, Retrospective Studies, Thyroid Hormones, Thyrotropin, Thyroxine, Case-Control Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.